Alopecia areata as another immune‐mediated disease developed in patients treated with tumour necrosis factor‐α blocker agents

Background  Tumour necrosis factor antagonists (anti‐TNF‐α) have demonstrated the efficacy in different chronic immune inflammatory disorders. Within the spectrum of adverse events, autoimmune diseases have been observed, including cases of alopecia areata (AA).

[1]  J. Weinberg.  Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-α blocker agents: Report of five cases and review of the literature , 2012 .

[2]  D. Nakagomi,et al.  Psoriasiform eruption associated with alopecia areata during infliximab therapy , 2009, Clinical and experimental dermatology.

[3]  N. Kanigsberg,et al.  Alopecia Areata following Adalimumab , 2009, Journal of cutaneous medicine and surgery.

[4]  N. Rao,et al.  Alopecia Areata During Etanercept Therapy , 2009, Ocular immunology and inflammation.

[5]  A. Drosos,et al.  Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors , 2009, Scandinavian journal of rheumatology.

[6]  A. Katoulis,et al.  Biologic Agents and Alopecia Areata , 2008, Dermatology.

[7]  F. Bérard,et al.  Alopecia Areata Universalis during Treatment of Rheumatoid Arthritis with Anti-TNF-α Antibody (Adalimumab) , 2008, Dermatology.

[8]  M. Khamashta,et al.  Autoimmune diseases induced by TNF-targeted therapies. , 2008, Best practice & research. Clinical rheumatology.

[9]  J. S. Henning,et al.  Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. , 2008, Arthritis and rheumatism.

[10]  N. Yawalkar,et al.  Alopecia Areata Universalis Elicited during Treatment with Adalimumab , 2008, Dermatology.

[11]  O. Dereure,et al.  Worsening Alopecia Areata and de novo Occurrence of Multiple Halo Nevi in a Patient Receiving Infliximab , 2008, Dermatology.

[12]  M. Khamashta,et al.  Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases , 2007, Medicine.

[13]  A. McMichael,et al.  Alopecia areata , 2007, International journal of dermatology.

[14]  G. Burmester,et al.  Development of alopecia areata universalis in a patient receiving adalimumab. , 2006, Archives of dermatology.

[15]  A. Tosti,et al.  Alopecia areata during treatment with biologic agents. , 2006, Archives of dermatology.

[16]  P. Joly.  The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. , 2006, Journal of the American Academy of Dermatology.

[17]  M. Phillips,et al.  Alopecia areata presenting in 2 kidney-pancreas transplant recipients taking cyclosporine. , 2005, Journal of the American Academy of Dermatology.

[18]  B. Strober,et al.  Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. , 2005, Journal of the American Academy of Dermatology.

[19]  W. Posten,et al.  Recurrence of alopecia areata in a patient receiving etanercept injections. , 2005, Archives of dermatology.

[20]  S. Nedorost,et al.  Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. , 2004, Archives of dermatology.

[21]  J. Pandey,et al.  Tumor necrosis factor alpha (TNF-α) gene polymorphism in alopecia areata , 1995, Human Genetics.

[22]  X. Mariette,et al.  Alopecia areata in a patient with rheumatoid arthritis treated with leflunomide. , 2002, The Journal of rheumatology.

[23]  G. Galbraith,et al.  Tumor necrosis factor alpha (TNF-alpha) gene polymorphism in alopecia areata. , 1995, Human genetics.

[24]  J. M. Weitzner.  Alopecia areata. , 1990, American family physician.

[25]  E. Allander.  Need, demand, and supply of medical care in a population sample of rheumatoid arthritis. , 1975, Scandinavian journal of rheumatology.